The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

Biochemical analyses provide an answer to the question of how the gut bacterium Morganella morganii might contribute to some ...